NRIX Stock Forecast & Price Target

Nurix Therapeutics is supported by a de-risked lead asset in bexobrutideg, which is advancing through registrational and combination studies in CLL while also expanding into high-value inflammatory disease settings such as MS and CSU. The company’s 3Q26 results reinforced that outlook, with $673.1M in revenue, $4.73 in EPS, and $1.1B in cash and cash equivalents, while Roche, Gilead, Sanofi, and Pfizer collaborations provide validation and non-dilutive funding. Its broader protein degradation platform, plus additional programs like NX-1607 and the STAT6 and IRAK4 partnerships, creates multiple catalysts and meaningful long-term upside beyond the lead oncology franchise.

Nurix Therapeutics is viewed negatively because the downside case depends on bexobrutideg failing to show competitive durability or revealing a safety concern, either of which could halt development and leave the shares valued near net cash with little pipeline value. The company’s prospects are heavily exposed to concentrated clinical, regulatory, and competitive risk across a single business segment, while partnership, legal, intellectual property, and supply chain issues could further disrupt execution. Added financial and dilution risk, along with broader macroeconomic and geopolitical pressures, reinforces the view that the pipeline may not justify meaningful equity value if lead assets disappoint.